Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-cash Items (2019 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Non-cash Items for 4 consecutive years, with $500000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 28.57% to $500000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $500000.0, a 28.57% decrease, with the full-year FY2025 number at $500000.0, down 28.57% from a year prior.
  • Non-cash Items was $500000.0 for Q4 2025 at Iovance Biotherapeutics, up from $300000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $59.5 million in Q1 2024 to a low of $300000.0 in Q3 2023.
  • A 3-year average of $15.1 million and a median of $3.5 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: skyrocketed 452.08% in 2024, then plummeted 99.5% in 2025.
  • Iovance Biotherapeutics' Non-cash Items stood at $31.7 million in 2023, then crashed by 97.79% to $700000.0 in 2024, then dropped by 28.57% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Non-cash Items are $500000.0 (Q4 2025), $300000.0 (Q3 2025), and $14.7 million (Q2 2025).